Efficacy of midostaurin combined with intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation in a patient with NPM1 and FLT3-TKD mutated acute myeloid leukaemia with clinical high-risk features

Elżbieta Patkowska(Institute for Transfusion Medicine), Barbara Nasiłowska‐Adamska, Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Monika Prochorec‐Sobieszek(Instytut Hematologii i Transfuzjologi)
Hematology in Clinical Practice
May 20, 2022
10.5603/hcp.2022.0004
Cited by 0

Related Papers

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|390
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy
|Blood|2022|129
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2023|106